Cite
HARVARD Citation
Chevallier, P. et al. (2015). 90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet. 2 (3), pp. e108-e117. [Online].